IL324796A - תרכובות מעכב parp1 - Google Patents
תרכובות מעכב parp1Info
- Publication number
- IL324796A IL324796A IL324796A IL32479625A IL324796A IL 324796 A IL324796 A IL 324796A IL 324796 A IL324796 A IL 324796A IL 32479625 A IL32479625 A IL 32479625A IL 324796 A IL324796 A IL 324796A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor compounds
- parp1 inhibitor
- parp1
- compounds
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2308970.9A GB2630970A (en) | 2023-06-15 | 2023-06-15 | PARP1 inhibitor compounds |
| PCT/EP2024/066049 WO2024256377A1 (en) | 2023-06-15 | 2024-06-11 | Parp1 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL324796A true IL324796A (he) | 2026-01-01 |
Family
ID=91539776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324796A IL324796A (he) | 2023-06-15 | 2025-11-19 | תרכובות מעכב parp1 |
Country Status (6)
| Country | Link |
|---|---|
| CN (1) | CN121532189A (he) |
| AU (1) | AU2024303288A1 (he) |
| GB (1) | GB2630970A (he) |
| IL (1) | IL324796A (he) |
| MX (1) | MX2025014493A (he) |
| WO (1) | WO2024256377A1 (he) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| EP1678169B1 (en) * | 2003-10-17 | 2009-07-22 | Astrazeneca AB | 4-(pyrazol-3-ylamino)pyrimidine derivatives for use in the treatment of cancer |
| WO2016012956A1 (en) * | 2014-07-24 | 2016-01-28 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| AU2016308717A1 (en) * | 2015-08-17 | 2018-01-25 | Lupin Limited | Heteroaryl derivatives as PARP inhibitors |
| EP3700901A1 (en) * | 2017-10-24 | 2020-09-02 | Genentech, Inc. | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof |
| MA57972B1 (fr) * | 2019-07-19 | 2025-05-30 | Astrazeneca Ab | Inhibiteurs de parp1 |
| CA3167899A1 (en) * | 2020-02-14 | 2021-08-19 | Xiangyong LIU | Quinolyl phosphine oxide compound, and composition and application thereof |
| WO2023004280A1 (en) * | 2021-07-19 | 2023-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Selective pyrazole lrrk2 inhibitors and methods for use thereof |
| AU2022326573A1 (en) * | 2021-08-13 | 2024-02-15 | Deciphera Pharmaceuticals, Llc | Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer |
| KR20240149429A (ko) * | 2022-02-16 | 2024-10-14 | 듀크 스트리트 바이오 리미티드 | 약학적 화합물 |
-
2023
- 2023-06-15 GB GB2308970.9A patent/GB2630970A/en active Pending
-
2024
- 2024-06-11 AU AU2024303288A patent/AU2024303288A1/en active Pending
- 2024-06-11 CN CN202480044270.4A patent/CN121532189A/zh active Pending
- 2024-06-11 WO PCT/EP2024/066049 patent/WO2024256377A1/en active Pending
-
2025
- 2025-11-19 IL IL324796A patent/IL324796A/he unknown
- 2025-12-02 MX MX2025014493A patent/MX2025014493A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2630970A (en) | 2024-12-18 |
| MX2025014493A (es) | 2026-01-07 |
| CN121532189A (zh) | 2026-02-13 |
| AU2024303288A1 (en) | 2025-12-18 |
| WO2024256377A1 (en) | 2024-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL324796A (he) | תרכובות מעכב parp1 | |
| SI4301468T1 (sl) | Spojine z zaviralcem fgfr3 | |
| IL313727A (he) | מעכבי פארפי | |
| GB202008201D0 (en) | Inhibitor compounds | |
| GB201914860D0 (en) | Inhibitor compounds | |
| IL314049A (he) | מעכבי parp7 | |
| IL290087A (he) | חומרים מעכבים | |
| GB202004960D0 (en) | Inhibitor compounds | |
| GB202200735D0 (en) | Compounds | |
| EP4504709A4 (en) | CDK9 inhibitors | |
| GB202110373D0 (en) | Inhibitor compounds | |
| GB201905328D0 (en) | Inhibitor compounds | |
| GB202307924D0 (en) | Inhibitor compounds | |
| GB202300881D0 (en) | Inhibitor compounds | |
| GB202315106D0 (en) | PARP1 inhibitor compounds | |
| GB202315093D0 (en) | PARP1 inhibitor compounds | |
| GB202311859D0 (en) | Parp1 inhibitor compounds | |
| GB202418023D0 (en) | Parp1 inhibitor compounds | |
| AU2024317419A1 (en) | Parp1 inhibitor compounds | |
| CA3297957A1 (en) | Parp1 inhibitor compounds | |
| CA3292545A1 (en) | Parp1 inhibitor compounds | |
| GB202312128D0 (en) | Deuterated parp1 inhibitor compounds | |
| GB202306601D0 (en) | Inhibitor compounds | |
| GB202215245D0 (en) | Inhibitor compounds | |
| GB202207972D0 (en) | Inhibitor compounds |